EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant

J S Guimbellot, Ashritha Chalamalla, Elizabeth Baker, K J Ryan, A Dowell, Saly Abouelenein, L E Bartlett, J Bergeron, G Turner, E P Acosta, K J Ramos

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2025.03.010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von J S Guimbellot und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Pulmonary and Sleep Medicine, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR, US…. Hauptthemen laut MEDLINE: Lung Transplantation, Cystic Fibrosis, Immunosuppressive Agents, Tacrolimus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CFTR modulators in post-transplant people with cystic fibrosis (pwCF) are less frequently used due to uncertainty regarding effectiveness and interactions with immunosuppressive agents. Elexacaftor/tezacaftor/ivacaftor (ETI) is a triple combination cystic fibrosis (CF) therapeutic with benefits in multiple organ systems where complications can impact lung transplant (LTx) outcomes, including malnutrition, diabetes, and sinus disease. ETI use in LTx recipients is variable. METHODS: We conducted a pharmacokinetics (PK) study of concentrations of ETI parent compounds and the four major metabolites (M23-ELX, M1-TEZ, M1-IVA, M6-IVA) in a prospective non-randomized observational study, with all transplant participants concomitantly taking tacrolimus for LTx immunosuppression and excluded if taking any other medication with known interactions (e.g., azole antifungals) and compared to a non-transplant group of pwCF. We completed non-compartmental analysis (NCA) for both groups and compared the transplant to non-transplant PK parameters, as well as to published data from the manufacturer for non-transplant pwCF. Area under the curve (AUC), average concentrations (Cavg), minimum and maximum concentrations, clearance, and other parameters were determined. RESULTS: Twelve transplant and fourteen non-transplant participants with CF completed the study. There were no significant differences between the mean values for any PK parameters for the transplant and non-transplant groups and no substantial differences in frequency of concentrations outside the therapeutic ranges in the two groups. CONCLUSIONS: Our data suggest there are not significant differences in concentrations of ELX, TEZ, IVA, or their major human metabolites in LTx recipients compared to non-transplant pwCF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationCystic FibrosisImmunosuppressive AgentsTacrolimusQuinolonesAminophenolsBenzodioxolesIndolesPyridinesPyrazolesHumansMaleFemaleAdultDrug CombinationsProspective StudiesChloride Channel AgonistsMiddle AgedQuinolines

Stichwörter der Autor:innen

Cystic FibrosisElexacaftorIvacaftorLung transplantPharmacokineticsTacrolimusTezacaftor

Substanzen

Immunosuppressive AgentsTacrolimusQuinolonesDrug CombinationsAminophenolsBenzodioxolesIndolesChloride Channel AgonistsPyridinesPyrazoles

Autor:innen und Institutionen

  • Department of Pediatrics, Section of Pulmonary and Sleep Medicine, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR, USA. Electronic address: jguimbellot@uams.edu.
  • Department of Pediatrics, Section of Pulmonary and Sleep Medicine, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR, USA; Gregory Fleming James Cystic Fibrosis Research Center, University o…
  • Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham (UAB) H…
  • Division of Clinical Pharmacology, University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Department of Pediatrics, Section of Pulmonary and Sleep Medicine, University of Arkansas for Medical Sciences, 1 Children's Way, Little Rock, AR, USA.
  • Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, USA.

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • Center for Clinical and Translational Science, University of Alabama at Birmingham
  • Cystic Fibrosis Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Cystic Fibrosis Research
  • National Institutes of Health

Zitieren

APA

Guimbellot, J. S., Chalamalla, A., Baker, E., Ryan, K. J., Dowell, A., Abouelenein, S., Bartlett, L. E., Bergeron, J., Turner, G., Acosta, E. P., & Ramos, K. J. (2025). Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.03.010

Vancouver

Guimbellot JS, Chalamalla A, Baker E, Ryan KJ, Dowell A, Abouelenein S, et al. Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.03.010

BibTeX
@article{Guimbellot2025,
  author = {Guimbellot, J S and Chalamalla, Ashritha and Baker, Elizabeth and Ryan, K J and Dowell, A and Abouelenein, Saly and Bartlett, L E and Bergeron, J and Turner, G and Acosta, E P and Ramos, K J},
  title = {Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2025.03.010}
}
Kostenlos starten →